APA (7th ed.) Citation

C, K., L, A., MA, V., C, S., E, M., L, B., . . . D, C. (2020). Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: Results from the Phase II ANRS 163 ETRAL study-authors' response. The Journal of antimicrobial chemotherapy, 75(12), 3699. https://doi.org/10.1093/jac/dkaa341

Chicago Style (17th ed.) Citation

C, Katlama, et al. "Dual Therapy Combining Raltegravir with Etravirine Maintains a High Level of Viral Suppression over 96 Weeks in Long-term Experienced HIV-infected Individuals over 45 Years on a PI-based Regimen: Results from the Phase II ANRS 163 ETRAL Study-authors' Response." The Journal of Antimicrobial Chemotherapy 75, no. 12 (2020): 3699. https://doi.org/10.1093/jac/dkaa341.

MLA (9th ed.) Citation

C, Katlama, et al. "Dual Therapy Combining Raltegravir with Etravirine Maintains a High Level of Viral Suppression over 96 Weeks in Long-term Experienced HIV-infected Individuals over 45 Years on a PI-based Regimen: Results from the Phase II ANRS 163 ETRAL Study-authors' Response." The Journal of Antimicrobial Chemotherapy, vol. 75, no. 12, 2020, p. 3699, https://doi.org/10.1093/jac/dkaa341.